Showing 11-20 of 114 results for "".
- From ASLMS: Advances in Infantile Hemangioma Diagnosis and Carehttps://practicaldermatology.com/news/from-aslms-advances-in-infantile-hemangioma-diagnosis-and-care/2474328/New guidelines from the International Society for the Study of Vascular Anomalies (ISSVA) offer more precise classification and improved multidisciplinary pathways for patient care. Kristen Kelly, MD, Professor of Dermatology and Surgery a
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Incyte Taps Dr. Pablo J. Cagnoni for New Leadership Rolehttps://practicaldermatology.com/news/incyte-taps-dr-pablo-j-cagnoni-for-new-leadership-role/2461704/Pablo J. Cagnoni, MD, is Incyte’s New President and Head of Research & Development, effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across its portfolio of programs in oncology, hematol
Case Report: Acquired Elastoic Hemangioma; Cosmetic Surgery Forum Resident Winners
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-acquired-elastoic-hemangioma-cosmetic-surgery-forum-resident-winners/21067/Infantile Hemangioma with Minimal or Arrested Growth with Superimposed Eczematous Dermatitis and Bacterial Infection: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/infantile-hemangioma-with-minimal-or-arrested-growth-with-superimposed-eczematous-dermatitis-and-bacterial-infection-a-case-report/23602/Curing the Blues: Resolution of the Tyndall Effect Through Removal of a Misplaced NASHA Filler with Hyaluronidase
https://practicaldermatology.com/topics/general-topics/PD0509_11-php/22833/Implantation of NASHA fillers too superficially can produce the Tyndall effect. Besides aesthetic elegance, longevity after injection and an excellent safety record, a significant advantage of NASHA fillers is that they are reversible when misplaced.Cosmetics Challenge: Six Strategies for Scientific Skincare, Part 2 of 2
https://practicaldermatology.com/topics/general-topics/cosmetics-challenge-six-strategies-for-scientific-skincare-part-2-of-2/21934/Clinicians who are familiar with scientifically proven skincare ingredients, knowledgeable about formulations, and adept at combining topical products can help patients achieve or maintain cosmetic rejuvenation goals.A Practical Primer for Dysport Part 3: Putting It All Together – Strategies for Success with Integrative Rejuvenation of the Upper Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/1109_10-php/22062/In-depth understanding of the aging process and appreciation of the fascinating interactions between facial anatomy and musculature are key to achieving the best results with our newest neurotoxin.A Practical Primer for Dysport, Part 1: Speaking the Language and Strategies for Success with the Glabella and Forehead
https://practicaldermatology.com/topics/general-topics/PD0709_09-php/22804/To gain the most benefit from the newest botulinum neurotoxin, clinicians need to think about the product in its own terms.